CA-DENODO
31.3.2021 09:02:05 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced Denodo Standard , a new data integration solution available on leading cloud marketplaces. The new offering leverages Denodo’s modern data virtualization engine to deliver superior performance and productivity, enabling real-time analytics and data services without replicating the data into another repository. Denodo Standard lowers the barriers to begin data integration by allowing organizations to purchase it directly from their cloud marketplace of choice—AWS, Microsoft Azure, and Google Cloud Platform. Its cloud infrastructure automation and flexible by the hour pricing enables both enterprises as well as small and medium businesses to rapidly deploy it without a large commitment of time and resources.
To begin a free trial of Denodo Standard on AWS, Azure, or Google Cloud click here .
Denodo Standard provides all the capabilities to quickly get data integration projects into production. Featuring an intuitive web user interface with a powerful no-code/low-code data design studio augmented by AI-powered suggestions and the option to choose from over 150 out-of-the-box connectors to various data sources, Denodo Standard delivers data quickly. The solution enables citizen integrators to connect to cloud data warehouses, data lakes, and SaaS applications, and combine the data from these disparate sources into a unified view for consumption by business users via dashboards and reports, or developers via APIs. Denodo’s modern data virtualization connects to data sources directly where the data resides, and provides an efficient way to make the integrated data securely available without the need to collect the data into an additional repository.
Key capabilities of Denodo Standard include:
- High performance data virtualization engine to integrate and deliver data in real time.
- Modern, unified Web UI with SSO (single sign on).
- Integrated Apache-Zeppelin-based data science notebook.
- Wizard-driven visual no-code/low-code design studio with auto-suggestions and autocomplete.
- Zero-code creation of virtual models to expose data from any source to any consumer much faster.
- No-code creation of data APIs: GraphQL, REST, OData with OAuth, SAML and Open API support.
- Rich Cloud Connectivity including: Amazon Redshift, Azure Synapse Analytics, Databricks Delta, Google BigQuery, cloud data stores such as AWS S3, Azure Data Lake Storage, and Google Cloud Storage and SaaS apps like Salesforce, Marketo and Google Analytics.
For organizations that need additional data management features, such as the machine learning data catalog, they can seamlessly upgrade their solution to the Denodo Platform and expand their data integration layer into an advanced logical data fabric.
Forrester VP, Principal Analyst and author of The Forrester Wave™: Enterprise Data Fabric, Q2 2020 , Noel Yuhanna wrote, “Denodo’s data fabric solution integrates key data management components including data integration, data ingestion, data transformation, data governance and security to support new and emerging use cases including Customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI and ML capabilities, and automation also continue to enhance across data fabric components.”
To understand the differences between the Denodo Standard and the Denodo Platform capabilities, click here .
“The goal of Denodo Standard is to enable organizations of all sizes to unlock the value of their data assets faster, and with a lower cost and resource commitment. By leveraging cloud infrastructure automation, usage-based pricing, and free trials in the cloud marketplaces, we have lowered barriers to start using Denodo for data integration,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We are excited to be able to bring the value of data virtualization to even more companies, especially small and medium-sized businesses, and we expect many of them to expand beyond their initial use quickly to the enterprise logical data fabric capabilities once they have realized the benefits and the rapid ROI Denodo provides.”
Please Tweet : News: @Denodo launches new fast and easy #dataintegration solution in the #cloud - “Denodo Standard”. Available on @awscloud @Azure @GoogleCloudTech. Free 30-day trial - https://www.denodo.com/en/denodo-platform/free-trials . Logical #datafabric #datavirtualization
About Denodo
Denodo is the leader in data virtualization providing agile, high-performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
